In a phase 2 study that included stage III and IV pancreatic cancer patients with germline BRCA1/BRCA2 and PALB2 mutations who were treated with cisplatin and gemcitabine with or without veliparib, response rates in the two arms were 74.1% and 65.2%, which did not differ statistically significantly with addition of the PARP inhibitor [51]. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.